Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...
Apr 14, 2021
0
2
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional ...
Apr 11, 2021
0
4
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, ...
Apr 8, 2021
0
11
Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. The main two subtypes are Hodgkin lymphoma and non-Hodgkin lymphoma. Because of breakthrough research, this once fatal diagnosis ...
Mar 31, 2021
0
2
Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.
Mar 19, 2021
0
2
White blood cells or lymphocytes are the soldiers of our immune system that patrol the body via the lymphatic system. While their primary role is to protect the body by scavenging invaders, they can sometimes go rogue and ...
Mar 2, 2021
0
2
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers ...
Feb 18, 2021
0
12
In people with central nervous system (CNS) lymphoma, cancerous B cells—a type of white blood cell—accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels. This disease is quite ...
Feb 17, 2021
0
11
Cell-based gene therapy Breyanzi (lisocabtagene maraleucel) has been approved to treat adults with certain types of large B-cell lymphoma who have not responded to other systemic treatment, the U.S. Food and Drug Administration ...
Feb 9, 2021
0
0
Among patients with lymphoma admitted to the hospital for severe COVID-19, those treated with B-cell-depleting therapies within the previous 12 months had an increased risk of prolonged hospital stay and death, according ...
Feb 4, 2021
0
3
